Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease

Neurology

Volumn 46, Issue 3, 1996, Pages 791-795

  Nagai, Y ^a   Ueno, S ^a,b   Saeki, Y ^a   Soga, F ^a   Hirano, M ^a   Yanagihara, T ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; BETA ACTIN; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; MESSENGER RNA; TRITIUM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION;

EID: 0029962158     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.3.791     Document Type: Article

References (37)

1. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankugen des extrapyramidalen Systems. Klin Wschr 1960;38:1236-1239.
2. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
3. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
4. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57: 562-566.
5. Kontur PJ, Al-Tikriti M, Innis RB, Roth RH. Postmortem stability of monoamines, their metabolites, and receptor binding in rat brain regions. J Neurochem 1994;62:282-290.
6. Guttman M. Dopamine receptors in Parkinson's disease. Neurol Clin 1992;10:377-386.
7. Dearry A, Gingrich JA, Fralardeau P, Fremeau RT Jr, Bates MD, Caron MG. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990;347:72-76.
8. Zhou QY, Grandy DK, Thambi L, et al. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990; 347:76-80.
9. Sunahara RK, Niznik HB, Weiner DM, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990;347:80-83.
10. Bunzow JR, Van Tol HHM, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336:783-787.
11. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347: 146-151.
12. Giros B, Martres MP, Sokoloff P, Schwartz JC. cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C R Acad Sci Paris 1990;311:501-508.
13. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
14. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614-619.
15. Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 1993;194: 368-374.
16. Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett 1992;314:23-25.
17. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992;13:61-69.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
20. Ng SY, Gunning P, Eddy R, et al. Evolution of the functional human β-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 1985;5:2729-2732.
21. Kinoshita T, Imamura J, Nagai H, Shimotohno K. Quantification of gene expression over a wide range by the polymerase chain reaction. Anal Biochem 1992;206:231-235.
22. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 1992;89:8155-8159.
23. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 1990;29:10351-10356.
24. 3H]spiroperidol binding sites in parkinsonism. Life Sci 1980;27:1587-1591.
25. Maloteaux JM, Laterre CE, Hens L, Laduron PM. Failure of a peripheral dopaminergic marker in Parkinson's disease. J Neurol Neurosurg Psychiatry 1983;46:1146-1148.
26. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes. J Neural Transm Park Dis Dement Sect 1993;5:107-116.
27. Reisine TD, Fields JZ, Yamamura HI. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci 1977;21: 335-344.
28. Rinne JO, Laihinen A, Lönnberg P, Marjamäki P, Rinne UK. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122.
29. Rabey JM, Grynberg E, Graff E. Changes of muscarinic cholinergic binding by lymphocytes in Parkinson's disease with and without dementia. Ann Neurol 1991;30:847-850.
30. Ferrero P, Rocca P, Eva C, et al. An analysis of lymphocyte3H-N-methyl-scopolamine binding in neurological patients. Brain 1991;114:1759-1770.
31. Shenkman L, Rabey JM, Gilad GM. Cholinergic muscarinic binding by rat lymphocytes: effects of antagonist treatment, strain and aging. Brain Res 1986;380:303-308.
32. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 1991; 564:203-219.
33. Lieberman A, Dziatolowski M, Kupersmith M, et al. Dementia in Parkinson's disease. Ann Neurol 1979;6:355-359.
34. Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.
35. Dubois B, Pillon B, Sternic N, Lhermitte F, Agid Y. Age-induced cognitive disturbances in Parkinson's disease. Neurology 1990;40:38-41.
36. Schmayss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 1993;90:8942-8946.
37. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 1994;648:222-228.